CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Activities
Net income (loss)	$ (88,720)	$ (75,738)	$ 131,762
Adjustments for non-cash items:
Non-cash interest expense on PDL liability			14,646
Non-cash PDL royalty revenue			(242,808)
Depreciation and amortization	109,375	85,737	12,025
Accretion of debt discount and debt issuance costs	17,673	15,629	4,200
Loss on prepayment of Senior Notes	5,777
Provision for inventory obsolescence	1,179	224
Loss on disposal of property and equipment		38	19
Stock-based compensation	17,172	14,228	8,930
Change in fair value of contingent consideration and unfavorable contract	(146)	(2,625)	2,791
Deferred income taxes	20,290	(44,166)	87,378
Cash paid for in-process research and development		25,000
Excess tax benefit from stock-based compensation	(637)	(4,625)	(3,190)
Other	611	358	288
Changes in assets and liabilities:
Accounts receivable	(30,931)	(44,117)	(15,453)
Receivables from collaborative partners	29	508	10,170
Inventories	(3,718)	9,329	1,689
Prepaid and other assets	(2,464)	6,085	(2,190)
Income taxes receivable	6,359	(2,332)	(4,030)
Accounts payable and other accrued liabilities	5,862	59,019	(4,579)
Accrued rebates, returns and discounts	10,478	85,348	17,143
Interest payable	(2,747)	15,992	2,683
Income taxes payable	59		(61,875)
Deferred revenue			(15,516)
Net cash (used in) provided by operating activities	65,501	143,892	(55,917)
Acquired in-process research & development expense		54,900
Investing Activities
Purchases of property and equipment	(2,860)	(1,715)	(599)
Acquisition of business		(1,050,011)
Acquisition of in-process research and development		(25,000)
Purchases of marketable securities	(68,818)	(116,209)	(73,754)
Maturities of marketable securities	115,207	84,884	27,046
Sales of marketable securities	2,007
Net cash provided by (used in) investing activities	45,536	(1,108,051)	(47,307)
Financing Activities
Proceeds from issuance of Convertible debt			345,000
Convertible debt issuance costs			(10,775)
Proceeds from the issuance of Senior Notes		562,063
Senior Notes issuance costs		(511)
Repayment of Senior Notes	(100,000)
Prepayment fees for repayment of Senior Notes	(5,000)
Proceeds from issuance of common stock	9,951	10,398	9,803
Excess tax benefit from stock-based compensation	637	4,625	3,190
Net cash (used in) provided by financing activities	(94,412)	576,575	347,218
Net increase (decrease) in cash and cash equivalents	16,625	(387,584)	243,994
Cash and cash equivalents at beginning of year	101,084	488,668	244,674
Cash and cash equivalents at end of period	117,709	101,084	488,668
Supplemental Disclosure of Cash Flow Information
Net cash (received) paid for income taxes	(14,425)	(4,048)	$ 58,318
Cash paid for interest	71,093	39,511
Non-cash consideration for in-process research and development		$ 29,900
Capitalized expenditures incurred but not yet paid	$ 402